December 3, 2020 | Jen Temple, Head of Communications | Reading Time: < 1 minute
Canexia Health’s Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. OncLive is a digital platform that offers resources and information to oncology professionals that they can use to help provide the best patient care.
In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
January 20, 2021
This technical note describes the NGS assays developed by Canexia Health for somatic testing of adult solid tumors and how they are made available through local laboratories via our proprietary technology transfer model.
January 11, 2021
With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test, which is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.
December 16, 2020
Earlier this year, Canexia Health launched Project ACTT, Access to Cancer Testing & Treatment in Response to COVID-19, with support from the Canadian federal government via the Digital Technology Supercluster. Through ACTT, we are leading a consortium of partners to speed up cancer testing in Canada for targeted treatment selection during the pandemic through minimally invasive circulating tumor (ctDNA) testing.